NBIX : Summary for Neurocrine Biosciences, Inc. - Yahoo Finance

U.S. Markets close in 19 mins.

Neurocrine Biosciences, Inc. (NBIX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
41.78-1.16 (-2.70%)
As of 3:41 PM EST. Market open.
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close42.94
Bid41.53 x 500
Ask41.58 x 200
Day's Range40.59 - 42.94
52 Week Range31.25 - 57.82
Avg. Volume918,653
Market Cap3.63B
PE Ratio (TTM)-28.75
Earnings DateN/A
Dividend & Yield0.00 (0.00%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswireyesterday

    Neurocrine Biosciences to Present at the 2016 BMO Capital Markets Prescription for Success Healthcare Conference

    SAN DIEGO, Dec. 7, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the 2016 BMO Capital Markets Prescription for Success Healthcare Conference in New York City. Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software.  A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month.

  • Hedge Funds Are Dumping CSRA Inc (CSRA)
    Insider Monkey2 days ago

    Hedge Funds Are Dumping CSRA Inc (CSRA)

    We at Insider Monkey have gone over 742 13F filings that hedge funds and prominent investors are required to file by the government. The 13F filings show the funds’ and investors’ portfolio positions as of September 30. In this article, we look at what those funds think of CSRA Inc (NYSE:CSRA) based on that data. […]

  • PR Newswire3 days ago

    Neurocrine Biosciences Announces INGREZZA™ (valbenazine) Long-Term Data to be Presented at the 55th Annual Meeting of the American College of Neuropsychopharmacology

    SAN DIEGO, Dec. 5, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX), a biotechnology company focused on neurological and endocrine related disorders, announced today that two abstracts representing additional data from several clinical trials of the investigational drug INGREZZATM (valbenazine) are being presented at the Annual Meeting of the American College of Neuropsychopharmacology in Hollywood, Florida. The posters include an evaluation of the safety and effectiveness of long-term dosing of INGREZZA in the treatment of tardive dyskinesia. "We are pleased to share the positive and compelling long-term treatment data of INGREZZA in tardive dyskinesia patients with the broader scientific community," said Chris O'Brien, M.D. Chief Medical Officer of Neurocrine Biosciences.